Get the Stockscreener App
0.474
8.16%
-0.0421
After Hours:
.47
-0.004
-0.84%
Moleculin Biotech Inc stock is traded at $0.474, with a volume of 1.96M.
It is down -8.16% in the last 24 hours and up +24.31% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.5161
Open:
$0.5199
24h Volume:
1.96M
Relative Volume:
0.57
Market Cap:
$23.46M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.031
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+2.66%
1M Performance:
+24.31%
6M Performance:
-35.17%
1Y Performance:
-80.49%
1-Day Range:
$0.4652
$0.52
1-Week Range:
$0.4617
$0.525
52-Week Range:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.474 | 25.55M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Is Moleculin Biotech Inc. stock overvalued by current metrics2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Technical signs of recovery in Moleculin Biotech Inc.Weekly Gains Report & Stepwise Entry/Exit Trade Alerts - newser.com
Moleculin Biotech Inc. stock momentum explainedJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Analyzing Moleculin Biotech Inc. with multi timeframe chartsWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
How to escape a deep drawdown in Moleculin Biotech Inc.2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Can Moleculin Biotech Inc. (MOL) stock stage a strong rebound this quarter - newser.com
How to build a dashboard for Moleculin Biotech Inc. stockInflation Watch & Safe Entry Point Identification - newser.com
Will earnings trigger a reversal in Moleculin Biotech Inc.Trade Performance Summary & Low Drawdown Investment Ideas - newser.com
Can Moleculin Biotech Inc. (MOL) stock hold up in economic slowdown2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Moleculin Biotech Secures $6 Million Through Warrant Agreement - MSN
Moleculin Biotech (NASDAQ:MBRX) Stock Rating Lowered by Wall Street Zen - Defense World
MBRXMoleculin Reports Second Quarter 2025 Financial Results and Highlights - ADVFN
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
What drives Moleculin Biotech Inc MOL stock priceFibonacci Extensions & High Profit Trading Plans - earlytimes.in
What analysts say about Moleculin Biotech Inc stockVolume Analysis Techniques & Low Risk Capital Growth Plans - earlytimes.in
What Technical Indicators Signal for GOCL Corporation Limited Next MonthAutomated Trading Signals & Discover Top Gainers in Every Sector - earlytimes.in
Moleculin Biotech Inc Stock Analysis and ForecastSupport Level Holds & Grow Generational Wealth With Ease - Early Times
What analysts say about Kekrops SA KE1 stockAnalyst Downgrades & Superior Growth Trading - Early Times
Moleculin Biotech announces issuance of Canadian patent covering Annamycin - Yahoo Finance
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - GlobeNewswire
Moleculin receives Canadian patent allowance for cancer drug Annamycin By Investing.com - Investing.com Nigeria
Moleculin Biotech Secures Canadian Patent for Annamycin - TipRanks
Moleculin Biotech (MBRX) Awaits Canadian Patent for Annamycin In - GuruFocus
Moleculin receives Canadian patent allowance for cancer drug Annamycin - Investing.com
First Non-Cardiotoxic Anthracycline: Moleculin's Annamycin Gains Canadian Patent Protection Until 2040 - Stock Titan
Certain Restricted Stock Units of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025. - MarketScreener
Certain Options of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025. - MarketScreener
Can Moleculin Biotech Inc. grow without dilutionJuly 2025 Recap & Advanced Swing Trade Entry Alerts - خودرو بانک
Moleculin Biotech (MBRX) Files to Sell 64.86 Million Common Shar - GuruFocus
Moleculin Biotech files prospectus for resale of common stockSEC Filing - MarketScreener
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moleculin Biotech Inc Stock (MBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):